2. Search Result
Search Result
Results for "

Amylin Receptor agonist

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

23

Peptides

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3462
    Cagrilintide
    3 Publications Verification

    		 CGRP Receptor Metabolic Disease
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
    Cagrilintide
  • HY-P0090
    Calcitonin (salmon)
    2 Publications Verification

    Salmon calcitonin

    		 CGRP Receptor Cancer
    Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
    Calcitonin (salmon)
  • HY-P10745
    Petrelintide

    ZP8396

    		 Amylin Receptor Metabolic Disease
    Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .
    Petrelintide
  • HY-P10798A
    Eloralintide sodium

    LY-3841136 sodium

    		 Amylin Receptor Calcium Channel Metabolic Disease
    Eloralintide sodium is an Amylin Receptor agonist. Eloralintide sodium selectively activates AMY1R and AMY3R in cells expressing human or rat AMY1R, AMY3R or CTR. Eloralintide sodium activates AMYRs and CTR in rats, inducing a sustained decrease in plasma Ca 2+ levels. Eloralintide sodium reduces appetite and body weight in both lean and obese rats. Eloralintide sodium can be used for research related to obesity .
    Eloralintide sodium
  • HY-P11274A
    Zenagamtide sodium

    Amycretin sodium; NN 9487 sodium

    		 Amylin Receptor Insulin Receptor GCGR Metabolic Disease
    Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
    Zenagamtide sodium
  • HY-P10745A
    Petrelintide acetate

    ZP8396 acetate

    		 Amylin Receptor Metabolic Disease
    Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .
    Petrelintide acetate
  • HY-P11245A
    NN1213 acetate

    		Amylin Receptor Metabolic Disease
    NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity .
    NN1213 acetate
  • HY-P10956
    Colulintide

    LY3541105

    		 Amylin Receptor CGRP Receptor Metabolic Disease
    Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity .
    Colulintide
  • HY-P11274
    Zenagamtide

    Amycretin; NN 9487

    		 Amylin Receptor GCGR Insulin Receptor Metabolic Disease
    Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
    Zenagamtide
  • HY-P11245
    NN1213

    		Amylin Receptor Metabolic Disease
    NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity .
    NN1213
  • HY-P11320
    Davalintide

    		Amylin Receptor CGRP Receptor Metabolic Disease
    Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .
    Davalintide
  • HY-P11269
    Lenbelintide

    		Amylin Receptor Metabolic Disease
    Lenbelintide is a dual amylin/calcitonin receptor agonist. Lenbelintide can be studied in research on obesity .
    Lenbelintide
  • HY-P4863
    Biotinyl-Amylin (human)

    		CGRP Receptor Neurological Disease Metabolic Disease
    Biotinyl-Amylin (human) is a biotin-labeled derivative of Amylin, amide, human (HY-P1070). Biotinyl-Amylin (human) acts as a competitive agonist for the Calcitonin Receptor (CTR) and for the Amylin receptors (AMY1, AMY2, and AMY3) formed by the association of CTR with RAMP1/2/3. By mimicking endogenous human amylin, Biotinyl-Amylin (human) binds to and activates CTR and AMY receptors, thereby initiating downstream signaling pathways involving cAMP, CREB, and ERK1/2, while retaining high-affinity receptor binding and activation capabilities. Biotinyl-Amylin (human) is primarily utilized in studies investigating the metabolic regulatory mechanisms underlying obesity and diabetes; it is also applicable to pharmacological research, receptor localization studies, and ligand-binding assays related to Amylin receptors in the context of Alzheimer's disease .
    Biotinyl-Amylin (human)
  • HY-P0090A
    Calcitonin (salmon) acetate

    Salmon calcitonin acetate

    		 CGRP Receptor Cancer
    Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .
    Calcitonin (salmon) acetate
  • HY-P0090S
    Calcitonin-13C6,15N4 (salmon) TFA

    Salmon calcitonin-13C6,15N4 TFA

    		 CGRP Receptor Metabolic Disease
    Calcitonin- 13C6, 15N4 (salmon) (Salmon calcitonin- 13C6, 15N4) TFA is 13C and 15N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .
    Calcitonin-13C6,15N4 (salmon) TFA
  • HY-179728
    Amylin agonist 1

    		Amylin Receptor CGRP Receptor Metabolic Disease
    Amylin agonist 1 (Example 239a) is a receptor 3 for pancreatic amyloid peptide (bAMY3R) agonist, and its EC50 for stimulating cAMP production in cells is 6.17 nM. Amylin agonist 1 is also a receptor for calcitonin (bCTR) agonist, with its EC50 being 8.58 nM. Amylin agonist 1 can be used for research on type 2 diabetes and obesity .
    Amylin agonist 1
  • HY-186104
    AMYR/CTR agonist 1

    		CGRP Receptor Amylin Receptor Metabolic Disease
    AMYR/CTR agonist 1 (Compound 195) is a pancreatic amylin receptor and calcitonin receptor (AMYR/CTR) agonist with EC50 values for pancreatic amylin receptor and calcitonin receptor cAMP of 99.5 and 6.16 pM respectively. AMYR/CTR agonist 1 can be used in the research of diseases such as type 2 diabetes and obesity .
    AMYR/CTR agonist 1
  • HY-185229B
    rel-CTR/AMYR agonist-1

    		Amylin Receptor CGRP Receptor Metabolic Disease
    rel-CTR/AMYR agonist-1 (Example 169) is an agonist of amylin and/or calcitonin receptor .
    rel-CTR/AMYR agonist-1
  • HY-P11665
    Batelintide

    		Amylin Receptor Metabolic Disease
    Batelintide is a dual amylin/calcitonin receptor agonist with antidiabetic effects .
    Batelintide
  • HY-P11586
    San45

    		Amylin Receptor Metabolic Disease
    San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
    San45
  • HY-P11830
    UDA-6

    		Amylin Receptor Metabolic Disease
    UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
    UDA-6
  • HY-P11843
    TPM004

    		Amylin Receptor CGRP Receptor Metabolic Disease
    TPM004 is an ultralong-acting, nonaggregating dual amylin (AMY3R) and calcitonin receptor (CTR) agonist with EC50 values of 0.5 and 0.7 pM. TPM004 induces weight loss, attenuates adiposity rebound, lowers glucose, and improves glucose homeostasis. TPM004 can be used for the research of obesity, diabetes .
    TPM004
  • HY-P11587
    BGM1812

    		Amylin Receptor CGRP Receptor Metabolic Disease
    BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .
    BGM1812
  • HY-P11610
    KBP-089

    		Amylin Receptor CGRP Receptor Metabolic Disease
    KBP-089 is a dual Amylin and Calcitonin Receptor agonist. KBP-089 reduces body weight, decreases adipose tissue mass and improves glucose tolerance in obese rats. KBP-089 also eliminates lipid accumulation in the liver and muscle, and ameliorates glycemic homeostasis and insulin sensitivity. KBP-089 is applicable to the research of diseases such as obesity and type 2 diabetes .
    KBP-089
  • HY-P11584
    KBP-066A

    		Amylin Receptor CGRP Receptor Metabolic Disease
    KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity .
    KBP-066A
  • HY-P11629
    KBP-336

    		Amylin Receptor CGRP Receptor Neurological Disease Metabolic Disease Inflammation/Immunology
    KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .
    KBP-336

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: